• 1. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 2. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 5. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines Pyrrolopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines

1H-Pyrrolo[2,3-b]pyridin-7-ium-7-olate Hydrate (CAS No. 1198285-78-7): A Comprehensive Overview

1H-Pyrrolo[2,3-b]pyridin-7-ium-7-olate hydrate (CAS No. 1198285-78-7) is a compound of significant interest in the fields of medicinal chemistry and pharmaceutical research. This compound, often referred to as a pyrrolopyridinium salt, has garnered attention due to its unique structural features and potential biological activities. In this article, we will delve into the chemical properties, synthesis methods, and recent research findings related to this compound.

The chemical structure of 1H-pyrrolo[2,3-b]pyridin-7-ium-7-olate hydrate is characterized by a fused pyrrole and pyridine ring system, with a positively charged nitrogen atom at the 7-position and a negatively charged oxygen atom at the same position, forming a zwitterionic structure. The presence of a hydrate moiety further adds to its stability and solubility in aqueous environments. This unique structure confers the compound with several interesting properties, including its ability to form stable complexes with various metal ions and its potential as a scaffold for drug design.

Synthesis of 1H-pyrrolo[2,3-b]pyridin-7-ium-7-olate hydrate has been explored through various routes. One common method involves the condensation of a substituted pyrrole with a pyridine derivative, followed by oxidation to form the zwitterionic salt. Recent advancements in synthetic chemistry have led to more efficient and environmentally friendly methods, such as the use of microwave-assisted synthesis and catalytic systems. These improvements have not only enhanced the yield and purity of the final product but also reduced the environmental impact of the synthesis process.

In terms of biological activity, 1H-pyrrolo[2,3-b]pyridin-7-ium-7-olate hydrate has shown promising results in several areas. Studies have demonstrated its potential as an antimicrobial agent, with activity against both Gram-positive and Gram-negative bacteria. The compound's ability to disrupt bacterial cell membranes and inhibit essential enzymes makes it a valuable candidate for developing new antibiotics. Additionally, research has indicated that 1H-pyrrolo[2,3-b]pyridin-7-ium-7-olate hydrate exhibits antiviral properties, particularly against enveloped viruses such as influenza and herpes simplex virus (HSV).

Another area of interest is the compound's anticancer activity. Preclinical studies have shown that 1H-pyrrolo[2,3-b]pyridin-7-ium-7-olate hydrate can induce apoptosis in various cancer cell lines, including those resistant to conventional chemotherapy. The mechanism of action appears to involve the modulation of key signaling pathways involved in cell proliferation and survival. These findings have sparked interest in further investigating the potential of this compound as a novel anticancer agent.

Pharmacokinetic studies have also been conducted to evaluate the absorption, distribution, metabolism, and excretion (ADME) properties of 1H-pyrrolo[2,3-b]pyridin-7-ium-7-olate hydrate. Results indicate that the compound has good oral bioavailability and favorable pharmacokinetic profiles, making it suitable for further development as a therapeutic agent. However, more extensive studies are needed to fully understand its behavior in vivo and to optimize its formulation for clinical use.

Recent clinical trials have begun to explore the safety and efficacy of 1H-pyrrolo[2,3-b]pyridin-7-ium-7-olate hydrate in treating various conditions. Early-phase trials have shown promising results, with no significant adverse effects reported at therapeutic doses. These findings have paved the way for larger-scale clinical studies to validate the therapeutic potential of this compound.

In conclusion, 1H-pyrrolo[2,3-b]pyridin-7-ium-7-olate hydrate (CAS No. 1198285-78-7) is a multifaceted compound with a wide range of potential applications in medicine. Its unique chemical structure and biological activities make it an attractive candidate for further research and development. As ongoing studies continue to uncover new insights into its properties and mechanisms of action, it is likely that this compound will play an increasingly important role in advancing therapeutic strategies for various diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)